Syngene International Limited: Business Overview, Financials & Competitive Analysis
Syngene International Limited scores 7/10 on the AskCyborg Cyborg Score (Solid). Syngene benefits from secular outsourcing trends in pharma R&D with solid execution capabilities, though growth may face cyclical headwinds. Strong market position in growing CDMO/DDMS sector with recurring revenue from blue-chip clients. Faces competition from established global CDMOs and Indian peers but benefits from structural demand for outsourced R&D.
What is Syngene International Limited's industry? Syngene International Limited (syngeneintl.com) operates in Contract Research and Manufacturing Services (CDMO/DDMS). AskCyborg classifies Syngene International Limited under Contract Research and Manufacturing Services (CDMO/DDMS) in its company registry.
Syngene International is India's leading integrated drug discovery, development and manufacturing services (DDMS) provider. The company offers preclinical and clinical services to global pharmaceutical and biotech cli...
Cyborg Score thesis
Syngene benefits from secular outsourcing trends in pharma R&D with solid execution capabilities, though growth may face cyclical...
Read the full analyst-debate transcript →Get the Latest Syngene International Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeSyngene International Limited Overview
Pro stress-test →Syngene International is India's leading integrated drug discovery, development and manufacturing services (DDMS) provider. The company offers preclinical and clinical services to global pharmaceutical and biotech clients, positioning itself as a critical bridge between innovation and commercialization in the global life sciences ecosystem.
Strategic Profile
Pro stress-test →Syngene competes on a platform model combining scientific expertise, regulatory capabilities, and manufacturing infrastructure for global pharma and biotech clients. Its competitive advantage lies in cost-effective execution, scientific quality, and established relationships with major pharmaceutical partners globally.
Competitive Landscape
Pro stress-test →Syngene competes with global CDMOs like Lonza, Catalent, and Fareva, as well as Indian peers including Dr. Reddy's Labs and other CRO/CDMO providers. Differentiation comes through cost efficiency, scientific credibility, and dedicated focus on discovery and development services.
Industry Context
Syngene International Limited operates in Contract Research and Manufacturing Services (CDMO/DDMS).
Key facts
Founded: 1993 · Headquarters: Bangalore, India · Employees: 3,500 · Revenue: $450M · Market cap: $2.8B